一项高剂量白细胞介素-2与皮下注射白细胞介素-2/干扰素对比的随机III期试验。 - Suppr

Suppr

超能文献

A randomized phase III trial of high dose interleukin-2 versus subcutaneous interleukin-2/interferon.

作者信息

Han Ken-Ryu, Pantuck Allan J, Belldegrun Arie S

出版信息

Curr Urol Rep. 2002 Feb;3(1):11-2. doi: 10.1007/s11934-002-0004-9.

DOI:10.1007/s11934-002-0004-9

PMID:12084213

Abstract

摘要

相似文献

A randomized phase III trial of high dose interleukin-2 versus subcutaneous interleukin-2/interferon.

Curr Urol Rep. 2002 Feb;3(1):11-2. doi: 10.1007/s11934-002-0004-9.

Current status of interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma.

Oncology (Williston Park). 2002 Nov;16(11 Suppl 13):4-10.

High-dose interleukin-2 in metastatic disease: renal cell carcinoma and melanoma.

Oncology (Williston Park). 2002 Nov;16(11 Suppl 13):3.

Subcutaneous interleukin-2 and interferon alfa administration in patients with metastatic renal cell carcinoma: final results of SCAPP III, a large, multicenter, phase II, nonrandomized study with sequential analysis design--the Subcutaneous Administration Propeukin Program Cooperative Group.

J Clin Oncol. 2003 Nov 1;21(21):3987-94. doi: 10.1200/JCO.2003.02.073.

Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma.

J Clin Oncol. 2005 Jan 1;23(1):133-41. doi: 10.1200/JCO.2005.03.206.

A systematic review of the relation between interleukin-2 schedule and outcome in patients with metastatic renal cell cancer.

Eur J Cancer. 2004 May;40(8):1127-44. doi: 10.1016/j.ejca.2004.02.010.

Survival in renal cell carcinoma: a randomized evaluation of tamoxifen vs interleukin-2, alpha-interferon (leucocyte) and tamoxifen.

Br J Cancer. 2000 Jan;82(1):246-7. doi: 10.1054/bjoc.1999.0952.

Interleukin-2 therapy of metastatic renal cell carcinoma: update of phase III trials.

Clin Genitourin Cancer. 2006 Sep;5(2):114-9. doi: 10.3816/CGC.2006.n.027.

Inhalation of interleukin-2 combined with subcutaneous administration of interferon for the treatment of pulmonary metastases from renal cell carcinoma.

Int J Urol. 1997 Jul;4(4):343-8. doi: 10.1111/j.1442-2042.1997.tb00205.x.

Renal-cell carcinoma.

N Engl J Med. 2006 Mar 9;354(10):1095-6; author reply 1095-6.

引用本文的文献

First-line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta-analysis.

Cochrane Database Syst Rev. 2023 May 4;5(5):CD013798. doi: 10.1002/14651858.CD013798.pub2.

Emerging molecular classification in renal cell carcinoma: implications for drug development.

Target Oncol. 2010 Jun;5(2):75-84. doi: 10.1007/s11523-010-0144-7. Epub 2010 Jul 20.

本文引用的文献

Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation.

N Engl J Med. 2000 Sep 14;343(11):750-8. doi: 10.1056/NEJM200009143431101.

Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids.

Nat Med. 2000 Mar;6(3):332-6. doi: 10.1038/73193.

Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie.

N Engl J Med. 1998 Apr 30;338(18):1272-8. doi: 10.1056/NEJM199804303381805.

Interleukin-2-based therapy for metastatic renal cell cancer: the Cytokine Working Group experience, 1989-1997.

Cancer J Sci Am. 1997 Dec;3 Suppl 1:S73-8.

Renal cell carcinoma: recent progress and future directions.

Cancer Res. 1997 Nov 15;57(22):5189-95.

Immunotherapy for renal cell carcinoma: the era of interleukin-2-based treatment.

Urology. 1995 Jun;45(6):911-24. doi: 10.1016/s0090-4295(99)80108-3.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验